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INTRODUCTION 
 
Benign Prostatic Hyperplasia is an important cause of Bladder Outlet 
Obstruction in males leading to chronic straining on micturition. Chronic 
straining for micturition can precipitate inguinal hernia in adults1,2. The 
occurrence of inguinal hernia and benign hyperplasia with accompanied 
urinary tract obstructive symptoms are related to age. Benign obstructing 
prostate enlargement also predisposes to hernia and aggravation of 
symptoms related to hernia.  Both Inguinal Hernia and symptomatic Benign 
Prostatic Hyperplasia are often found together in increased frequency in 
elderly 2, 3. On the basis of this evidence significant correlation between 
inguinal hernia and obstructing benign prostate enlargement may be 
expected 2.  
Several standard General Surgical text books give chronic straining 
due to BPH as an etiological factor for inguinal hernia in elderly male 
population1,5,13. But some of the studies showed that their occurrence 
together is considered a chance co-existence rather than cause and 
effect3,14,15,16. This study is aimed to find out whether Benign Prostatic 
Hyperplasia is a significant risk factor for developing Inguinal Hernia in 
males. 
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AIM OF THE STUDY 
 
To find out the incidence of Benign Prostatic Hyperplasia among male patients 
with inguinal hernia. 
To find out whether there is any causal association between Benign Prostatic 
Hyperplasia and Inguinal Hernia. 
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REVIEW OF LITERATURE 
 
INGUINAL HERNIA 
A hernia is a protrusion of a viscus or part of a viscus through an abnormal 
opening in the wall of its containing cavity 1.  
The external abdominal hernia being the commonest variety, most frequent 
of it is the inguinal hernias. Important components of hernia are the hernia orifice 
and the hernia sac. Hernial orifice is the defect in the innermost apponeurotic layer 
of the abdominal wall and the hernia sac is the out pouching of the peritoneum. 
Neck of the sac corresponds to the hernial orifice. 
INGUINAL HERNIA – ANATOMY 4, 5 
The groin region is a complex network of muscles, ligaments, and fascia that 
are interwoven in a complex fashion. Inguinal canal is 4 to 6cm long and is 
situated in the anteroinferior portion of the pelvic basin. Shaped like a cone, its 
base is at the superolateral margin of the basin, with its apex pointed 
inferomedially towards the symphysis pubis. The canal begins intra abdominally 
on the deep aspect of the abdominal wall, where the spermatic cord passes through 
a hiatus in the transeversalis fascia (in females, this is round ligament). This hiatus 
is termed the deep or internal inguinal ring. The canal ends at the superficial aspect 
of the abdominal musculature at the superficial ring, which is a defect in the 
external oblique apponeurosis. 
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 Anteriorly the wall of the inguinal canal is formed by the external oblique 
apponeurosis and the internal oblique muscle laterally. Posteriorly, the wall is 
formed by the fusion of the transeversalis fascia and the transverses abdominus 
muscle, although up to one fourth of persons are found to have only the 
transeversalis fascia covering the posterior wall. Roof is formed by an arch formed 
by the fibres of the internal oblique muscle and the floor is formed by the inguinal 
ligament and the lacunar ligament. 
The inguinal ligament is also known as the Paupart ligament and is 
comprised of the inferior fibres of the external oblique apponeurosis. The ligament 
stretches from the anterior superior iliac spine to the pubic tubercle. Cooper’s 
ligament is otherwise known as the pectineal ligament. It is the lateral portion of 
the lacunar ligament that is fused to the periosteum of the pubic tubercle. The 
lacunar ligament, or the ligament of Gimbernat, is the triangular fanning out of the 
inguinal ligament as it joins the pubic tubercle. 
Nerves of interest in the inguinal region are the ilioinguinal, iliohypogastric 
and genital branch of genitofemoral nerve. The ilioinguinal and iliohypogastric 
nerve arise together from first lumbar nerve (L1). The ilioinguinal nerve enters the 
inguinal canal by piercing the internal oblique muscle and exit through the 
superficial ring. The nerve supplies the skin of the upper and medial thigh and in 
males it also supplies the penis and upper scrotum, while supplying the mons pubis 
and labium majus in females. The iliohypogastric nerve arises from T12-L1 and 
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follows the ilioinguinal nerve. After the iliohypogastric nerve pierce the deep 
abdominal wall, it courses between the internal oblique and transeversus 
abdominis, supplying both. Then it branches in to a lateral and an anterior 
cutaneous branch, which pierces the internal oblique apponeurosis and then 
external oblique apponeurosis above the superficial inguinal ring. The 
Genitofemoral nerve arises from L1-L2, courses along the retroperitoneum, and 
emerges on the anterior aspect of the psoas. It then divides into genital and femoral 
branches. The genital branch enters the inguinal canal just lateral to inferior 
epigastric vessels. In males it travels through the superficial inguinal ring and 
supplies the scrotum and the cremaster muscle. In females, it supplies the mons 
pubis and labium majora. 
Myopectineal Orifice of Fruchaud 4: Fruchaud believed that all hernias of the 
groin begin within the groin; in an area he named the myopectineal orifice. This 
area in the groin is bounded superiorly by Arch of internal oblique muscle and 
transversus abdominis muscle, laterally by the Iliopsoas muscle, medially by 
lateral border of rectus muscle and its anterior lamina and inferiorly Pubic pectin. 
Running diagonally through the myopectineal orifice is the inguinal ligament. The 
orifice is covered by the transeversalis fascia. 
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INGUINAL HERNIA – EPIDEMIOLOGY 1, 5, 6, 7 
 Inguinal hernia repair is one of the most commonly performed procedures by 
a General Surgeon. It is difficult to estimate the exact prevalence of inguinal hernia 
in the general population, but an overwhelming majority of the procedures are 
done in males 90% vs. 10% in females. Approximately 70% of femoral hernia 
repairs are done in females but inguinal hernia repairs are 5 times more common in 
females than femoral hernia repairs. Incidence of hernia have a bimodal 
distribution in males with peaks before 1 year of age and then again after 40 years 
of age. Indirect inguinal hernias are the most common hernias in both men and 
women; a right-sided predominance exists. 
Exact prevalence of inguinal hernia in Indian population is not available. An 
extrapolated statistical analysis from a study given by Asia Pacific Hernia Society 
states that around 1,95,7850 people are affected by inguinal hernia in India7. 
INGUINAL HERNIA – ETIOLOGY 
 Inguinal hernias may be considered congenital or acquired diseases. A 
number of studies have attempted to delineate the precise cause of inguinal hernia 
formation; however the risk factors are likely multifactorial. 
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Presumed Causes of Groin Herniation2, 3, 5, 13 
Coughing  Birth weight < 1500g 
COPD Positive family history 
Obesity  Valsalva maneuver 
Straining – constipation Ascitis 
Straining – prostatism Upright posture 
pregnancy Connective tissue diseases 
Defective collagen Synthesis Previous Right Lower Quadrant 
incision 
Arterial aneurysms Cigarette smoking 
Heavy lifting Physical exertion 
 Congenital hernias are considered to be an impedance to the normal 
development, rather than acquired weakness. During the normal course of 
development, the testes descent from the intraabdominal space into the scrotum in 
the third trimester. Their descent is preceded by the gubernaculums and a 
diverticulum of peritoneum, which protrude through the inguinal canal and 
ultimately becomes the processus vaginalis. Processus vaginalis usually closes 
between 36 and 40 weeks, failure of which results in patent processus vaginalis 
and this explains the high incidence of indirect inguinal hernia in preterm babies. 
 13 
 
 The introduction of continuous ambulatory peritoneal dialysis for renal 
failure has demonstrated, as did ascites, that a patent processus vaginalis or canal 
of nuck, if subjected to increased intraabdominal pressure over a period of time, 
will dilate and produce a Hydrocele or hernia. Carcinomatosis, decompensated 
liver or heart disease can therefore present as recent onset herniation. 
 Microscopic examination of skin of inguinal hernia patients demonstrated 
significantly decreased ratios of collagen type I to collagen type III. Type III 
collagen have less tensile strength than type I collagen. Additional analysis of the 
skin revealed disaggregated collagen tracts with decreased collagen fibre density. 
These connective tissue defects are seen systemically – in skin, lung, pericardium 
etc. Most common cause for these changes is found to be heavy smoking and the 
condition is termed as metastatic emphysema. Therefore long term tobacco 
exposure is a risk for hernia formation. Patients with congenital connective tissue 
disorders like Ehler Danlos Syndrome, due to defective connective tissue, leading 
to less tensile strength of their tissues, can have hernia formation. 
 Historically, hernia causation was attributed to a mechanical disparity 
between visceral pressure and the resistance of the musculature. Cooper not only 
identified Transeversalis fascia, but also pointed out it was the last barrier to groin 
hernia formation. Therefore factors that increases intraabdominal pressure – cough, 
obesity, unusual exertion, pregnancy, prostatism in old age patients, over the long 
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time can lead on to hernia formation. However this occurs in a combination with a 
patent processus vaginalis or through age related weakness of the abdominal 
musculature is not clear. Both Inguinal Hernia and symptomatic Benign Prostatic 
Hyperplasia are often found together in increased frequency in elderly 2, 3. On the 
basis of this evidence significant correlation between inguinal hernia and 
obstructing benign prostate enlargement may be expected. 
PROSTATE – ANOTOMY4, 9 
 The prostate gland is formed around the end of the third month (first 
trimester) from the epithelium of the future prostatic urethra. The epithelium 
proliferates and penetrates the surrounding mesenchyme, which is the future fibro 
muscular prostatic tissue.  
 The classical description of the adult prostate is that it has the size, shape, 
and consistency of a large chestnut. The form of the prostate is that of a 
compressed inverted cone: pyramidal, having a base and an apex. It is located 
between the vesical neck of the bladder and the apex of the urogenital diaphragm. 
The normal weight of the prostate in a young adult is from 17 to 19g. The numbers 
4, 3, 2 are useful as a mnemonic for remembering the transverse, vertical, and 
sagittal dimensions in centimetres, respectively, of the gland. The prostate is 
enveloped by extra peritoneal connective tissues that cover the thin anatomic 
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capsule (true capsule) of the organ, and it in turn envelops the proximal male 
urethra. The prostate is fixed to its location by Puboprostatic ligaments, Urogenital 
diaphragm, Bladder, Prostatic sheath and Fascia of Denonvilliers.  
Prostatic Surfaces 
 There are four prostatic surfaces: one posterior, one anterior, and two 
inferolateral. The posterior surface is flat transversely and convex vertically. It is 
separated from the rectal ampulla by the bilaminar fascia of Denonvilliers. This 
surface is characterized by a midline groove that is wider toward the base of the 
gland, and serves to partially separate the gland posteriorly into left and right lobes. 
The posterior surface may be palpated by digital rectal examination. The 
vesicoprostatic junction is located at the upper border of the posterior surface. The 
narrow and convex anterior surface is located between the apex and the base. 
Multiple large veins separate this surface from the symphysis pubis. The avascular 
puboprostatic ligaments are fibrous cords, wide or narrow. They connect the upper 
limits of the anterior surface of the prostate to the pubic bone, at the right and left 
sides of the cartilaginous area. The right and left inferolateral surfaces are 
embraced by the anterior part of the levator ani muscles. They are fixed to the 
levator by the arcus tendineus of the fascia pelvis, sagittal connective tissue bands 
between the ischial spine, and the pubic bone. Here there is a very rich venous 
network and fibrous tissue which contributes part of the lateral prostatic sheath. 
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Prostatic Urethra 
 The prostatic urethra begins at the urethral meatus at the apex of the trigone 
of the bladder. This opening is crescent-shaped, invaginated posteriorly by a 
protuberance caused by the underlying glandular tissue (median lobe of the 
prostate), thus forming the uvula vesicae. This is continuous with a posterior 
midline urethral ridge, or crest, in the urethra. The urethral ridge has a distinctly 
expanded portion called the verumontanum, or seminal colliculus.  
Prostate – Structure 
 McNeal described four regions or zones in the prostate: peripheral, central, 
transition, and anterior fibromuscular stroma. The urethra is the key anatomic 
entity defining these regions. Posterior to the urethra is the glandular area. Anterior 
to the urethra is the fibromuscular area; that is, the ventral portion of the glandular 
prostatic tissue is covered by the fibromuscular stroma.  
Peripheral Zone: It is likely that the glands of this zone develop from the 
urogenital sinus and drain into the prostatic urethra. Nearly 75% of the glandular 
prostate, the peripheral zone surrounds most of the central zone and much of the 
urethra; in other words, it surrounds the posterior and lateral areas of the prostate 
gland. Its glands drain into the prostatic urethra. This zone is formed by multiple 
tubuloalveolar glands. The long, narrow ducts of this zone branch into small, 
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round, regular acini with smooth, nonseptate walls. Epithelium is simple columnar; 
its pale cells have distinct borders and basally-placed small, dark nuclei. Most 
carcinomas develop in the peripheral zone. 
Central Zone: Ducts of this zone are probably of wolffian origin. The central 
zone, which is nearly 25% of the glandular prostatic parenchyma, envelops the 
ejaculatory ducts and extends toward the base of the urinary bladder. The central 
zone is continuous with the peripheral zone and, like the peripheral zone, is formed 
by several tubuloalveolar glands (mucosal, submucosal, main prostatic) which are 
located around the urethra. The acinar tissue consists of large, irregularly shaped 
spaces; the walls have intraluminal ridges or septa. The cells of the central zone 
differ significantly from those of the peripheral zone. They have more opaque, 
granular cytoplasm and less distinct cell membranes. Their cell length varies, they 
have an irregular luminal border, and they appear more crowded. Their nuclei, 
which are slightly larger than those of the peripheral zone and stain paler, are 
displaced to variable levels from the basement membrane. Carcinoma seldom 
arises in the central zone. 
Transition Zone: Glands in the transition zone are formed from the junction of the 
proximal and distal urethral segments. This zone is less than 5% of the glandular 
prostate. The transition zone is composed of two minute glandular regions which 
are lateral to the preprostatic sphincter and directly related to the proximal urethral 
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segment. The periurethral region is related to this zone and to the junction of the 
proximal and distal urethral segments. Periurethral ducts, which are responsible for 
the genesis of benign prostatic hyperplasia, are present. In this zone one observes a 
minimal number of glands. The transition zone and other periurethral glands are 
the exclusive site of origin of benign prostatic hypertrophy. The area near or within 
the sphincter almost invariably produces the most numerous and largest nodules. 
Ten to twenty percent of carcinomas may develop in the transition zone.  
Stroma: The anterior fibromuscular stroma is nonglandular. It constitutes ⅓ of the 
prostatic tissue within the prostatic capsule but is in continuity with the detrusor 
muscle of the neck of the urinary bladder. It is heavily fixed with the anterior 
surfaces of the three glandular zones, and represents the periurethral gland region. 
The fibromuscular stroma is composed of striated and smooth muscles, as well as 
elastin and collagen.  
Capsules of the Prostate 
 There are three capsules of the prostate; two (the true and false) are anatomic 
the third is pathologic. The true capsule is a very thin covering surrounding the 
gland in toto. The false capsule (periprostatic fascia or prostatic sheath) is an 
extraperitoneal fascia (visceral layer of endopelvic fascia). This capsule is 
continuous with 4 fasciae; anteriorly, fascia of the bladder, puboprostatic ligament, 
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laterally, arcus tendineus of the fascia pelvis, Posterior: fascia of Denonvilliers and 
inferiorly, superior fascia of the urogenital diaphragm. Between the true and false 
capsules is a venous plexus, the prostatic or pudental venous plexus.  
Part of the normal aging process is progressive prostatic growth due to 
benign prostatic hyperplasia (BPH), the peripheral part of the prostate becomes 
compressed against the surrounding endopelvic connective tissue, forming a 
surgical capsule (pathologic capsule). When enucleation of the prostate is 
performed, the plane between the compressed peripheral tissue and the 
adenomatous tissue permits removal of the adenoma, leaving behind the peripheral 
condensed prostatic tissue and the anatomic capsule.  
Prostate Vascular Supply 
Arterial Supply: The blood supply of the prostate is derived primarily from 
inferior vesical artery. A branch of this artery enters the prostate laterally at the 
prostatovesical junction. This artery divides into two branches, the peripheral and 
the central. The peripheral branch serves the majority of the prostatic parenchyma; 
the central branch supplies the urethra and the periurethral tissues. Other arteries 
contributing rami to the prostate are the internal pudental and middle rectal 
arteries. The middle rectal artery is considered to be poorly named, since most of 
its blood goes to the prostate gland.  
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Venous Drainage: There is a rich venous plexus (prostatic plexus) between the 
prostate gland and the prostatic sheath. It communicates with the internal iliac 
venous system and the presacral veins. The prostatic venous plexus receives the 
deep dorsal penile vein and the veins of the base of the bladder. The vesical and 
internal iliac veins receive most of the venous blood. 
Lymphatic Drainage: From the prostatic acinus, large intraprostatic trunks are 
formed. These penetrate the prostatic capsule and form the periprostatic lymphatic 
plexus. This plexus yields lymphatic vessels which follow the vascular network of 
the prostatovesical arteries. The lymph vessels that follow the prostatovesical 
arteries travel to the internal iliac lymph nodes. The vessels also travel to the 
presacral lymph nodes and, occasionally, to the external iliac lymph nodes. 
Prostate – Innervation 
 The preganglionic sympathetic nerve supply to the smooth muscle of the 
seminal vesicles, ejaculatory ducts, and prostate gland arises in the intermediate 
gray area of spinal cord levels L1 and L2 (or L3). Postganglionic fibres arise in the 
preaortic or pelvic plexuses. The sympathetic fibres cause contraction of the 
smooth muscle and expulsion of seminal fluid. Parasympathetic fibres from sacral 
cord levels S2, S3, and S4 synapse in pelvic ganglia and periprostatic ganglia. 
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They act perhaps to dilate blood vessels and stimulate secretion from glands of the 
genital system, including the prostate. 
Histology of Prostate 
 Seventy percent of the weight of the prostatic mass is glandular epithelium. 
Thirty percent is fibromuscular, mainly non-striated. The glandular part contains 
ducts and acini which are lined with columnar epithelium and drain in the posterior 
and lateral walls of the prostatic urethra. In all regions, ducts and acini are lined 
with secretory epithelium, with a layer of basal cells and interspersed endocrine-
paracrine cells beneath. The peripheral zone has small, rounded, uniform glands. 
The central and transitional zones have very large and irregular acini. 
Physiology of Prostate 
The prostate gland secretes a milk like alkaline fluid. This fluid is very 
important for the fertilization of the ovum, since sperm within both the ductus 
deferens and vaginal tissue produce fertilization-inhibiting acidity. Guyton stated 
that prostatic fluid most likely neutralizes the acidity of the fluids of the ductus 
deferens and vagina after ejaculation, enhancing the motility and fertility of the 
sperm. The prostatic fluid also contains citric acid, calcium, phosphorus, and other 
substances. 
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BENIGN PROSTATIC HYPERPLASIA 9 
 
 Benign prostatic hyperplasia (BPH) is a pathologic process that contributes 
to, but is not the sole cause of, lower urinary tract symptoms (LUTS) in aging men. 
Despite intense research efforts in the past five decades to elucidate the under lying 
etiology of prostatic growth in older men, cause-and-effect relationships have not 
been established.  For example, androgens are a necessary but not a clearly 
causative effect of BPH.  
 The nomenclature of voiding dysfunction in aging men is confusing and 
often inaccurate. The term BPH should be used with reference to the histologic 
process of hyperplasia, which can be demonstrated microscopically.  Men with 
benign prostatic enlargement (BPE) presumably have an increase in total prostate 
volume because of BPH. BPE may or may not produce clinically significant LUTS 
and may or may not produce urodynamically proven bladder outlet obstruction.  
ETIOLOGY OF BENIGN PROSTATIC HYPERPLASIA 
 BPH is but one cause of the LUTS in aging men commonly, and probably 
incorrectly, referred to as prostatism. Histopathologically, BPH is characterized by 
an increased number of epithelial and stromal cells in the periurethral area of the 
prostate. The observed increase in cell number may be due to epithelial and 
stromal proliferation or to impaired programmed cell death leading to cellular 
accumulation.  Androgens, estrogens, stromal-epithelial interactions, growth 
 23 
 
factors and neurotransmitters may play a role, either singly or in combination, in 
the etiology of the hyperplasic process.  
Hyperplasia  
 In a given organ, the number of cells, and thus the volume of the organ, is 
dependent upon the equilibrium between cell proliferation and cell death.  An 
organ can enlarge not only by an increase in cell proliferation but also by a 
decrease in cell death.  The relative role of cell proliferation in human BPH is 
questioned because there is no clear evidence of an active proliferative process. 
Although it is possible that he early phases of BPH are associated with a rapid 
proliferation of cells, the established disease appears to be maintained in the 
presence of an equal or reduced rate of cell replication and increased expression of 
antiapoptotic pathway genes. Androgens not only are required for normal cell 
proliferation and differentiation in the prostate but also actively inhibit cell death. 
The hyperplasia results in a remodelling of the normal prostatic architecture. 
Epithelial budding from pre-existing ducts and the appearance of mesenchymal 
nodules characterize the early stages of the process. When the proliferating cell 
matures through a process of terminal differentiation, they have a finite life span 
before undergoing programmed cell death.  In this paradigm, the aging process 
induces a block in this maturation process so that the progression to terminally 
differentiated cells is reduced, reducing the overall rate of cell death.  
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The Role of Androgens 
 Although androgens do not cause BPH, the development of BPH requires 
the presence of testicular androgens during prostate development, puberty, and 
aging patients castrated prior to puberty or who are affected by a variety of genetic 
disease that impair androgen action or production do not develop BPH. It is also 
known that prostatic levels of dihydrotestosterone (DHT) as well as the androgen 
receptor (AR) remain high with aging despite the fact that peripheral levels of 
testosterone are decreasing.  Moreover, androgen withdrawal leads to partial 
involution of established BPH.  Assuming normal ranges, there is no clear 
relationship between the concentration of circulating androgens and prostate size in 
aging men.  
 In the brain, skeletal muscle, and seminiferous epithelium, testosterone 
directly stimulates androgen-dependent processes.  In the prostate, however, the 
nuclear membrane bound enzyme steroid 5 α –reductase converts the hormone 
testosterone into DHT, the principal androgen in this tissue. Ninety percent of total 
prostatic androgen is in the form of DHT, principally derived from testicular 
androgens. Inside the cell, both testosterone and DHT bind to the same high-
affinity androgen receptor protein.  The hormone receptor then binds to specific 
DNA binding sites in the nucleus, which results in increased transcription of 
androgen-dependent genes and ultimately stimulation of protein synthesis.  
Conversely androgen withdrawal from androgen-sensitive tissue results in a 
 25 
 
decrease in protein synthesis and tissue involution.  Besides inactivation of key 
androgen-dependent genes (e.g., prostate-specific antigen), androgen withdrawal 
leads to the activation of specific genes involved in programmed cell death.  
Despite the importance of androgens in normal prostatic development and 
secretory physiology, there is no evidence the either testosterone or DHT serves as 
the direct mitogen for growth of the prostate in older men. However, many growth 
factors and their receptors are regulated by androgens.  Thus the action of 
testosterone and DHT in the prostate is mediated indirectly through autocrine and 
paracrine pathways. 
Androgen Receptors 
The prostate, unlike other androgen dependent organs, maintains its ability 
to respond to androgens throughout life.  AR levels in the prostate remain high 
throughout aging. In fact, there is evidence to suggest that nuclear Androgen 
Receptor levels may be higher in hyperplastic tissue than in normal controls. Age-
related increases in estrogen, as well as other factors, may increase AR expression 
in the aging prostate, leading to further growth. 
5 α reductase enzyme 
Two steroid 5 α reductase have been discovered, each encoded by a separate 
gene. Type 1 5 α-reductase, the predominant enzyme in extraprostatic tissues, such 
as skin and liver, Type 2 5α-rducatase is the predominant prostatic 5α-reductase. It 
is exquisitely sensitive to inhibition by finasteride and dutasteride. The type 2 
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enzyme is critical to normal development of the prostate and hyperplastic growth 
later in life.  
Immunohistochemical studies with type 2 5α-reducatase specific antibodies 
show primarily stromal cell localization of the enzyme.  Epithelial cells uniformly 
lack type 2 protein. The stromal cell plays a central role in androgen-dependent 
prostatic growth and that the type 2 5α-reductase enzyme within the stromal cell is 
the key androgenic amplification step. Thus, a paracrine model for androgen action 
in the gland is evident.  In addition, it is possible that circulating DHT produced in 
the skin and liver may act on prostate epithelial cells in a true endocrine fashion.  
Polymorphism in the type 2 5α-reductase enzyme (SRD5A2) has been 
reported, but their linkage to BPH is uncertain.  Androgen withdrawal may 
partially exert its effect on the prostate through vascular effects.  There is indirect 
evidence to suggest that abnormalities in the prostatic vascular system produced by 
other disease states may be a risk factor of BPH.  
The Role of Estrogens  
 There is animal model evidence to suggest that estrogens play a role in the 
pathogenesis of BPH. The role of estrogens in the development of human BPH, 
however, is less clear.   
 Serum estrogen levels increase in men with age, absolutely or relative to 
testosterone levels.  There is also suggestive evidence that intraprostatic levels of 
estrogen are increased in men with BPH. Patients with larger volumes of BPH tend 
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to have higher levels of estradiol in the peripheral circulation.  At present, 
however, the role of estrogens in human BPH is not as firmly established as the 
role of androgens.   
Stromal-Epithelial Interaction 
 There is abundant experimental evidence to demonstrate that prostatic 
stromal and epithelial cells maintain a sophisticated paracrine type of 
communication.  This is strong evidence that one class of stromal cell excretory 
protein partially regulates epithelial cell differentiation.  Thus, BPH may be due to 
a defect in a stromal component that normally inhibits cell proliferation, resulting 
in loss of a normal “braking” mechanism for proliferation.   
 The process of new gland formation in the hyperplastic prostate suggests a 
“reawakening” of embryonic processes in which the underlying prostatic stroma 
induces epithelial cell development.  Many of the prostatic stromal-epithelial 
interactions observed during normal development and in BPH may be mediated by 
soluble growth factors or by the extracellular matrix (ECM). CRY61 (An Early 
Immediate Reponses Gene) is an ECM-associated protein that promotes adhesion, 
migration, and proliferation of epithelial and stromal cells.  CRY61 expression is 
significantly increased in human BPH tissues and is induced by lysophosphatidic 
acid (and endogenous lipid growth factor). 
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Growth Factors: 
 Growth factors are small peptide molecules that stimulate, or in some cases 
inhibit, cell division and differentiation processes; Cells that respond to growth 
factors have on their surface receptors specific for that growth factor that in turn 
are linked to a variety of transmembrane and intracellular signalling mechanisms. 
Interaction between growth factors and steroid hormones may alter the balance of 
cell proliferation versus cell death to produce BPH. 
 In addition to FGF-2, acidic FGF (FGF-1), Int-2 (FGF-3), keratinocyte 
growth factor (KGF, FGE-7), transforming growth factors (EGF) have been 
implicated in prostate growth. Similar mechanisms may be operational in BPH, 
leading to the accumulation of epithelial cells. If cellular proliferation is a 
component of the BPH process, it appears that growth stimulator factors such as 
FGR-1, -2, -7, and -17 families; vascular endothelial growth factor (VEGF); and 
insulin-like growth factor (IGF) may play a role, with DHT augmenting or 
modulating the growth factor effects.  In contrast, TGF-β, which is known to 
inhibit epithelial cell proliferation, may normally exert a restraining influence over 
epithelial proliferation that is lost or down regulated in BPH.  
 Although data on the absolute level of growth factor and growth factor 
receptors in hyperplastic as opposed to normal tissue are conflicting, it is likely 
that growth factors play some role in the pathogenesis of BPH.  
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Other Signalling Pathways 
 Sympathetic signalling pathways are important in the pathophysiology of 
LUTS.  In addition, there is increasing evidence that sympathetic pathways may be 
important in the pathogenesis of the hyperplastic growth process.  Alpha blockade, 
in some model systems, can induce apoptosis. Adrenergic pathways can also 
modulate the smooth muscle cell phenotype in the prostate all the components of 
the renin-angiotensin system (RAS) are present in prostatic tissue and may be 
activated in BPH.  Either with or without sympathetic modulation, local RAS 
pathways may contribute to cell proliferation and smooth muscle contraction.  
The Potential Role of Inflammatory Pathways and Cytokines in Benign 
Prostatic Hyperplasia 
 An additional source of growth factors in human BPH tissue may be the 
inflammatory cell infiltrates seen in many men with BPH. Thayer and associates 
(1992) reported extensive infiltration of human BPH tissues by activated T cells.  
Peripheral blood and tumor infiltrating T cells are known to express VEGF, a 
potent epithelial mitogen T cells are known to produce and secrete a variety of 
other growth factors including HB-EGF and bFGF/FGF-2. Thus T cell present in 
the local prostate environment were thought to be capable of secreting potent 
epithelial and stomal mitogens that promote stromal and glandular hyperplasia 
 A large number of cytokines and their receptors are seen in BPH tissue. 
Specifically, significant levels of IL-2, IL-4, IL-7, IL-17, interferon γ (IFEN- γ) 
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and their relevant receptors are found in BPH tissue. Macrophage inhibitory 
cytokine I is expressed in normal prostate tissue but significantly down regulated 
in BPH. To date, however, no firm cause-and-effect relationships have been 
established between prostatic inflammation and related cytokine pathways and 
stromal-epithelial hyperplasia.  
Genetic and Familial Factors 
 There is substantial evidence the BPH has an inheritable genetic component.  
Sanda and colleagues (1994) conducted a retrospective case-control analysis of 
surgically treated BPH patients and control subjects at Johns Hopkins.  The BPH 
patients were men whose respected prostate weights were in the highest quartile 
(greater than 37 g) and whose age at prostatectomy was in the lowest quartile.  The 
hazard-function ratio for surgically treated BPH among first-degree male relatives 
of the controls was 4.2 (95% confidence interval [CI] demonstrating a very strong 
relationship 9, 10. 
A segregation analysis showed that the results were most consistent with an 
Autosomal Dominant inheritance pattern. Approximately 50% of men undergoing 
prostatectomy of BPH at less the 60 years of age could be attributable to 
inheritable form of disease.  In contrast, only about 9% of men undergoing 
prostatectomy of BPH at more than 60 years of age would be predicated to have a 
familial risk 9, 10. However, the specific gene or genes involved in familial BPH or 
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that contribute to the risk of significant prostatic enlargement in sporadic disease 
remain to be elucidated.  
Other Etiologic Factors 
 Androgens and soluble growth factors are clearly not the only important 
factors for the development of BPH.  All mammalian prostates studied have 
testosterone, DHT, and AR as well as most of the known growth factor signalling 
pathways; however, only dog and man develop BPH.  Interestingly, another 
glandular organ that remains androgen responsive throughout life, the seminal 
vesicle, does not develop hyperplasia.  Obviously, other mechanisms or cofactors 
must be present in these two unique species making them susceptible to the 
disease.  Non androgenic substances from the testis perhaps transmitted through 
the vas deferens or deferential blood vessels, for example, may play some role. 
Prolactin has long been speculated to play a role in BPH because of the known 
effects of this hormone on prostate cells in vitro.  However, despite the 
documented presence of prolactin receptors in the human prostate and low 
circulating levels of the hormone, the role of prolactin in human prostate disease is 
unclear.  
PATHOPHYSIOLOGY OF BENIGN PROSTATIC HYPERPLASIA9 
 The pathophysiology of BPH is complex. Prostatic hyperplasia increases 
urethral resistance, resulting in compensatory changes in bladder function.  
However, the elevated detrusor pressure required to maintain urinary flow in the 
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presence of increased outflow resistance occurs at the expense of normal bladder 
storage function.  Obstruction induced changes in detrusor function, compounded 
by age- related changes in the bladder and nervous system function, lead to urinary 
frequency, urgency, and nocturia, the most bothersome BPH-related complaints.  
Pathology9 
Anatomic Features:  BPH first develops in the periurethral transition zone of the 
prostate.  The transition zone consists of two separate glands immediately external 
to the preprostatic sphincter and the main urethral wall at the point of urethral 
angulation near the verumontanum. 
 All BPH nodules develop either in the transition zone or in the periurethral 
region. Although early transition zone nodules appear to occur either as the disease 
progresses and the number of small nodules increases, they can be found in almost 
any portion of the transition or periurethral zone.  However, the transition zone 
also enlarges with age unrelated to the development of nodules. 
 One of the unique features of the human prostate is the presence of the 
prostatic capsule, which plays an important role in the development of LUTS, In 
the dog, the only other species known to develop  naturally occurring BPH, 
symptoms of bladder outlet obstruction and urinary symptoms rarely develop 
because the canine prostate lacks a capsule.  Presumably the capsule transmits the 
“Pressure” of tissue expansion to the urethra and leads to an increase in urethral 
resistance.  Thus, the clinical symptoms of BPH in man may be due not only to 
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age-related increases intraprostatic size but also to the unique anatomic structure of 
the human gland.  Clinical evidence of the importance of the capsule can be found 
in series that clearly document that incision of the prostatic capsule (transurethral 
incision of the prostate) results in a significant improvement in outlaw obstruction, 
despite the fact that the volume of the prostate remains the same.  
Histologic Features: BPH is a true hyperplastic process.  Histologic studies 
document and increase in the cell number the majority of early periurethral nodules 
are purely stomal in character.  It is unclear whether these early stromal nodules 
contain mainly fibroblast-like cells or whether differentiation toward a smooth 
muscle cell type is occurring.  In contrast, the earliest transition zone nodules 
represent proliferation of glandular tissue that may be associated with an actual 
reduction in the relative amount of stroma. 
 These glandular nodules are apparently derived from newly formed small 
duct branches that bud off from existing ducts, leading to a totally new ductal 
system within the nodule.  This type of new gland formation is quite rare outside 
embryonic development. This proliferative process leads to a tight packing of 
glands within a given area as well as an increase in the height of the lining 
epithelium.  
 During the first 20 years of BPH development, the disease may be 
predominantly characterized by an increased number of nodules, and the 
subsequent growth of each new nodule is generally slow. Then a second phase of 
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evolution occurs in which there is a significant increase in the size of nodules.  In 
the first phase, the glandular nodules tend to be larger than the stromal nodules.  In 
the second phase, when the size of individual nodules is increasing, the size of 
glandular nodules clearly predominates.  
The Bladder’s Response to obstruction 
 Current evidence suggests that the bladder’s response to obstruction is 
largely an adaptive one.  However, it is also clear that many lower tract symptoms 
in men with BPH or prostate enlargement are related to obstruction – induced 
changes in bladder function rather than to outflow obstruction directly.    
 Obstruction-induced changes in the bladder are of two basic types.  First, the 
changes that lead to detrusor instability or decreased compliance and second, the 
changes associated with decreased detrusor contractility, which are associated with 
further deterioration in the force of the unitary stream, hesitancy, intermittency, 
increased residual urine, and (in a minority of cases) detrusor failure. Acute urinary 
retention should not be viewed as inevitable result of this process.  Many patients 
presenting with acute urinary retention have more than adequate detrusor function, 
with evidence of a precipitating event leading to the obstruction.  
 There is considerable evidence that the response of the detrusor smooth 
muscle cell to stress (increased load related to outlet obstruction) is not as adaptive 
as the response of skeletal muscle to stress. In the latter case, a relatively normal 
repertoire of contractile protein genes are upregulated and an increased number of 
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normally organized contractile units assemble in the muscle cell.  In the detrusor 
smooth muscle cell load induced hypertrophy leads to change in myosin heavy 
chain isoform expression and to a signification alteration in the expression of a 
variety of thin filament-associated proteins.  
 In addition to obstruction – induced changes in the smooth muscle cell and 
ECM of the bladder, there is increasing evidence that obstruction may modulate 
neural – detrusor responses as well 
EPIDEMILOGY AND NATURAL HISTORY 
Definitions 
 The study of epidemiology is concerned with the distribution and 
determinants of diseases in humans.  Form this evolve the components for 
descriptive epidemiology, description of disease incidence, mortality, and 
prevalence by person, place, and time, and analytic epidemiology, the search for 
determinants of disease risk that may sever to increase prospects for prevention.  
 There is no globally accepted epidemiologic definition of BPH, and thus 
prevalence and incidence rates must be viewed in the context of the definitions 
chosen by the investigator reporting the data.  
Cross-Sectional Studies of Clinical Prevalence: 
 Descriptive epidemiology relies on the presence of a single universally 
accepted definition of “disease.” The definitions of BPH, however, have undergone 
several changes in the past decade, and, at present, no single criterion can be 
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applied.  In the past, the term “prostatism” was used, incorrectly referring to the 
prostate as the sole source of the typical LUTS founds in aging men.  It has been 
pointed out that there are at least three interrelated phenomena that can be assessed 
independently, namely the symptoms (formerly called prostatism), enlargement of 
the prostate gland, and presence of obstruction.  In a given patient, all three, two of 
the three, or only one of the three entities might be present.  Paul Abrams coined 
the term lower urinary tract symptoms to replace the old and inappropriate term 
prostatism.  The same patients then can be further classified based on the degree of 
prostatic enlargement as measured by digital rectal examination (DRE), transrectal 
ultrasonography (TRUS), or magnetic resonance imaging (MRI) and lastly by the 
presence and degree of bladder outlet obstruction as measured by flow rate 
recordings or invasive pressure flow studies.  
 The diagram 9, 11 shown below attempts to illustrate the difficulties in using 
different disease definitions.  Of all men older than 40, a certain proportion 
develop histology hyperplasia of the prostate, that is BPH.  Of those, some but not 
all develop LUTS, and other may have LUTS for reasons other than BPH.  Prostate 
enlargement occurs in some but again not all men with histologic BPH and LUTS, 
and some men with enlarged glands may not have any symptoms at all.  Lastly, 
urodynamically proven obstruction may be present in men who have either one 
several or all of histology BPH, LUTS, and enlarged glands, yet other may have 
obstruction without having any evidence of BPH. 
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   In addition to the mere enumeration of symptoms by frequency of 
occurrence, the bother associated with the symptoms, interference with activities of 
daily living, and the impact the symptoms have on quality of life are important 
distinguishing characteristics.  
 Accordingly, when studying the prevalence of clinical BPH admittedly an 
imprecise tem describing the constellation of LUTS, bother, interference, quality of 
life impact, with or without enlargement, obstruction, and so forth disease 
definitions may be applied that take either one or several of these items into 
consideration.  For the subsequent discussion it is important to recognize that very 
few if any clear cut-off points have been established that allow differentiation 
between disease absent or present states (e.g., one might argue that a prostate 
volume over 30mlconstitutes clinical BPH, but others might argue for a higher or 
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lower cut-off point; similar observations apply for symptoms and degrees of 
obstruction).  
Symptom Severity and Frequency9, 17 
 Form a pragmatic point of view, studies of symptom severity and frequency 
are of greatest importance in a disease that is rarely fatal and is characterized by its 
effects on the quality of life. The development, validation, and translation with 
cultural and Linguistic validation of the standardized, self-administered seven item 
American Urological Association (AUA) symptom index (also known as the 
International Prostate Symptom Score [IPSS]) has been a pivotal event in the 
clinical research on LUTS and BPH. 
 With the total score running from 0 to 35 pints, patients scoring 0 to 7 points 
are classified as mildly symptomatic, those scoring from 8 to 19 points as 
moderately symptomatic, and those scoring 20 to 35 points as severely 
symptomatic.  The instrument is an integral part of virtually every epidemiologic 
study as well as treatment studies in the field, and the availability of validated 
translations in many common languages allows cross-cultural comparisons of 
unprecedented scope.  Socioeconomic factors do not seem to influence responses 
to the questionnaire and fundamentally similar responses are obtained when the 
questionnaire is self-administered, read to the patient mailed in, or administered in 
some other way.  
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In the past 
month: 
Not 
at 
All 
Less 
than 
1 in 5 
Times 
Less 
than 
Half 
the 
Time 
Abou
t 
Half 
the 
Time 
More 
than 
Half 
the 
Time 
Alm
ost 
Alwa
ys 
Yo
ur 
sco
re 
Incomplete Emptying: 
How often have you 
had the sensation of not 
emptying your bladder? 
0 1 2 3 4 5  
Frequency: How often 
have you had to urinate 
less than every two 
hours? 
0 1 2 3 4 5  
Intermittency: How 
often have you found 
you stopped and started 
again several times 
when you urinated? 
0 1 2 3 4 5  
Urgency: How often 
have you found it 
difficult to postpone 
urination? 
0 1 2 3 4 5  
Weak Stream: How 
often have you had a 
weak rinary stream? 
0 1 2 3 4 5  
Straining: How often 
have you had to strain 
to start urination? 
0 1 2 3 4 5  
  
Nil 
    1 
Time 
    2 
Time 
   3 
Time 
   4 
Time 
   5 
Time 
 
 Nocturia: How many 
times did you typically 
get up at night to 
urinate? 
0 1 2 3 4 5  
Total IPSS 
Score 
       
Score:  1-7: Mild  8-19: Moderate  20-35: Severe 
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Apart from these 7 questions regarding symptom severity International 
Prostate Symptom Score also contains an 8th question which is a Quality Of Life 
(QOL) question. This question is added as the International Scientific Committee 
(SCI), under the patronage of the World Health Organization (WHO) and the 
International Union Against Cancer (UICC), recommends the use of only a 
single question to assess the quality of life. The answers to this question range from
 “delighted” to “terrible” or 0 to 6. 
Quality of Life Due to 
Urinary Symptoms 
Deli
ghte
d 
Plea
sed 
Most
ly 
Satis
fied 
Mixe
d 
Mostly 
Dissatis
fied 
Unh
app
y 
Ter
ribl
e 
If you were to spend the 
rest of your life with 
your urinary condition 
just the way it is now, 
how would you feel 
about that? 
1 2 3 4 5 6  
 
A very large international investigation of LUTS in Asian men was 
undertaken by Homma and colleagues (1997) in which 7588 men from Japan, 
China, Taiwan, Korea, the Philippines, Thailand, Singapore, Pakistan, India, and 
Australia were, queried.  The finding of 18%, 29% , 40% and 56% of men in their 
40s, 50s, 60s, and 70s having moderate to severe symptoms is line with the other 
studies reported both form Asia and from Europe and North America. 
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Prostate Size 
 Prostate size can be estimated by DRE, although the reliability across 
observers is in general considered poor.  In addition, DRE tends to underestimate 
true prostate size as determined by TRUS or other imaging modalities.  The 
magnitude of the underestimation increases with increasing prostate size for 25% 
up to 50% or more For the purpose of epidemiologic studies, TRUS and MRI 
measurements are preferred, although MRI measurement are somewhat expensive 
when attempting cross-sectional examinations of populations.  TRUS volume 
measurements using the prostate ellipsoid volume formula are the most widely 
accepted measure of prostate volume with reasonable statistical performance 
characteristics, particularly when performed by a single or several well trained 
examiners. 
Measures of obstruction 
 Subvesical obstruction can be measured only by invasive pressure-flow 
studies; nonintubated free flow rates provide at best an indirect measure for the 
probability of obstruction being present. Unfortunately, no large-scale cross-
sectional studies have been done employing pressure-flow tests because of the 
invasive and costly nature of the test, and it is unlikely that significant data sets 
will ever become available.  
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 It is commonly accepted that a maximum flow rate of less than 10ml/sec 
indicates a high probability of obstruction and a flow rate of greater than 15ml/sec 
indicate a low probability, with 10 to 15 ml/sec presenting an intermediate range. 
Post Residual Urine Volume19, 20 
 One of the important subjects of tests for urinary incontinence is the post 
void residual urine volume (PVR), the amount of urine left after urination. 
Normally, about 50 mL or less of urine is left; more than 200 mL is a definite sign 
of abnormalities. Measurements in between require further tests. The most 
common method for measuring PVR is with a catheter, a soft tube, which is 
inserted into the urethra within a few minutes of urination. PVR can also be 
measured using transabdominal ultrasonography.  
 A study on the distribution of Post – void residual urine volume in randomly 
selected men published in the Journal Of Urology suggests little variation in the 
distribution of post-void residual urine volume across age groups or levels of 
urinary symptoms and peak urinary flow rate. However, a somewhat stronger 
relationship was found between residual urine and prostate volume. 
 
Prostate-specific antigen (PSA) 8, 12, 18 
Prostate-specific antigen (PSA) is a protein produced by normal prostate 
cells. This enzyme participates in the dissolution of the seminal fluid coagulum and 
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plays an important role in fertility. The highest amounts of PSA are found in the 
seminal fluid; some PSA escapes the prostate and can be found in the serum. 
The level of PSA in the blood can be determined by a simple blood test. 
PSA blood test results are reported as nanograms per millilitre or ng/ml. Normal 
level usually range from 0 ng/ml to 4 ng/ml.  
Rising levels of PSA in serum are associated with prostate cancer. The PSA 
level also tends to rise in men with benign prostatic hyperplasia (BPH) and is a 
good marker for prostate volume. PSA levels are usually elevated in men with 
acute bacterial prostatitis. 
As BPH is a true hyperplasia, more cells produce a greater amount of PSA. 
It has been suggested that many PSA elevations detected and investigated in 
clinical practice may in fact be due to BPH leading to the argument that PSA is a 
better marker of BPH than of prostate cancer. One approach to distinguish the two 
conditions when PSA is elevated is to perform a free-to-total PSA ratio: more free 
PSA than complexed PSA suggests BPH rather than prostate cancer. A ratio of 
around 20% or greater for free PSA is considered more likely to represent BPH 
than cancer. PSA is discussed further in the investigations section below. 
Correlations between Parameters 
 As noted, all relevant parameters such as symptom severity and frequency, 
bother, interference, disease-specific health-related quality of life (HROQOL), 
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maximum flow rate, and prostate volume tend to worsen with advancing age. 
However, reported correlations between these parameters as well as urodynamic 
pressure-flow studies are in general weak with some exceptions.  Strong 
correlations exist between measures of symptom severity and frequency (I-PSS 
score), bother, disease-specific HRQOL, and interference scores.  
 With the exception of age, correlations between various measures of LUTS 
and BPH are modest in community based population studies and weak in BPH 
clinic and trial populations, not precluding, however, a clinical meaningful 
relationship.  The relationship between serum PSA and prostate volume is 
moderate and dependent on age and racial and ethnic origin.  Neither symptoms 
nor flow rate nor prostate volume measures can predict presence and degree of 
obstruction reliably.  
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MATERIALS AND METHODS 
 
150 male patients aged more than 50 years admitted with inguinal hernia to 
the 6th Surgical Unit of Government Rajaji Hospital, Madurai between September 
2009 and September 2011 are selected as cases.  
Inclusion criteria were, 
1. Male sex, 
2. Age more than 50 years, 
3. Those with inguinal hernia. 
Exclusion criteria were, 
1. Female sex, 
2. Age ≤ 50 years, 
3. Known case of connective tissue disorders, 
4. Known case of BPH, who are already on drugs or have had any form of 
surgery for BPH in the past. 
5. Presence of complications of hernia, such as irreducibility, strangulation or 
obstruction. 
The method of selection was to select the first 150 male patients in the order 
date of their admission to the Government Rajaji Hospital without any other 
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methods of randomization. The case selection was independent of the side of the 
hernia or whether the hernia is unilateral, bilateral or recurrent. 
 Every week, after selecting cases, the corresponding number of control 
subjects was selected randomly from the patients admitted to the 6th Surgical Unit 
of Government Rajaji Hospital, Madurai for conditions other than inguinal hernias 
so as to make a control group of 150 subjects. In case, required number of controls 
was not available from the corresponding week’s admission, the required number 
of controls was selected from the previous week’s admission. 
The inclusion criteria for the controls include, 
1. Male sex, 
2. Age > 50 years, 
3. Not seriously ill. 
The exclusion criteria for the controls include, 
1. Female sex 
2. Age ≤ 50 years, 
3. Known case of connective tissue disorders, 
4. Known case of BPH, who are already on drugs or have had any form of 
surgery for BPH in the past, 
5. Presence of inguinal hernia unilateral, bilateral or recurrent, 
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6. History of surgery done for inguinal hernia in the past, 
7. Seriously ill or bedridden patient. 
Informed written consent was obtained from each of the cases and controls. All 
subjects were interviewed and examined by the single observer. 
Very few if any clear cut off points have been established that allow 
differentiation between disease absent and present states [9]. Hence for this study 
three independent variable - International Prostate Symptom Score, Prostate-
specific antigen (PSA), and prostate volume were taken and prevalence of BPH in 
cases and controls were found out for each of the three variables separately. 
International Prostate Symptom Score: 
International Prostate Symptom Score was obtained by reading out the 
questionnaire and answer options in the prescribed format as many of the study 
subjects were not able to read the questionnaire and mark the answers in the 
prescribed format. Each question was read out with its answer options and score 
for each question was marked separately and the sum is calculated to find out the 
International Prostate Symptom Score of each subject. The International Prostate 
Symptom Score (IPSS) is an 8 question (7 symptom questions + 1 quality of life 
question) written screening tool used to screen for, rapidly diagnose, track the 
symptoms of, and suggest management of the symptoms of the disease benign 
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prostatic hyperplasia (BPH). The score of 7 symptom questions were added to get 
the International Prostate Symptom Score (IPSS). 
IPSS result of 7 symptoms questions 
Score Correlation 
0 – 7 Mildly symptomatic 
8 – 19 Moderately symptomatic 
20 – 35  Severely symptomatic 
 
 Subjects who are moderately or severely symptomatic i.e., those with 
International Prostate Symptom Score ≥8 were taken as having significant benign 
prostatic hyperplasia. Those who are mildly symptomatic i.e. those with 
International Prostate Symptom Score <8 were taken as having no significant 
benign prostatic hyperplasia.  
 
PROSTATE SPECIFIC ANTIGEN8. 
Prostate-specific antigen (PSA) is an enzyme produced by the prostate 
gland. Normally, PSA is secreted in small amounts into the bloodstream. However, 
larger amounts of PSA are released when the prostate gland is enlarged, infected, 
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or diseased. The level of PSA in the blood can be determined by a simple blood 
test. PSA blood test results are reported as nanograms per millilitre or ng/ml. 
Normal level usually range from 0 ng/ml to 4 ng/ml.  
The blood samples from the subjects were taken before doing Digital Rectal 
Examination. Subjects with Prostate-specific antigen values > 4ng/ml were taken 
as having significant benign prostatic hyperplasia in this study. Those subjects 
whose Prostate-specific antigen values ≤ 4ng/ml were taken as having no 
significant benign prostatic hyperplasia. 
PROSTATE VOLUME: 
 The normal weight of the prostate in a young adult is from 17 to 19g4. Since 
1cm³ of prostate tissue equals approximately 1g of prostate tissue, >20cc of 
prostate volume was taken as significant benign prostatic hyperplasia in this study9. 
Since Trans Rectal Ultra sonogram is not available in our hospital trans abdominal 
ultra sonogram was used to measure the Prostate size in this study So subjects with 
prostate volume > 20cc are taken as having significant benign prostatic hyperplasia 
and those with prostate size ≤ 20cc are taken as having no significant benign 
prostatic hyperplasia. 
 International Prostate Symptom Score (IPSS), Serum Prostate-specific 
antigen (PSA), and Prostate volume were found out for all cases and controls.  
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The prevalence of benign prostatic hyperplasia in both cases and controls 
were done for each of the three variables studied here. Univariate analysis of the 
association between inguinal hernia and benign prostatic hyperplasia was done for 
each of the three variables separately.  
Chi Square test is used to find out the association and P values were 
calculated for each variable. A P value <0.05 is taken as statistically significant. 
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ANALYSIS AND DISCUSSION 
 
The study was conducted over a period of 2years from 1st August, 2009 to 
31st August, 2011. A total no of 150 cases and 150 controls were selected. The 
cases were all males, aged between 51years and 85years with a mean age of 
62.42years.  
The age distribution of cases was as follows. 
Age group 51 – 60 years 61- 70 yrs 71 - 80 yrs > 80 yrs 
Number of 
cases 
70 58 21 1 
 
 The controls were all male subjects, aged between 51years and 83 years with 
a mean age of 63.56. 
The age distribution of controls was as follows. 
Age group 51 – 60 years 61- 70 yrs 71 - 80 yrs > 80 yrs 
Number of 
cases 
56 61 28 5 
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The age distribution of cases 
 
 
The age distribution of controls 
 
51 - 60 yrs
61- 70 yrs
71 - 80 yrs
> 80 yrs
51 - 60 yrs
61 - 70 yrs
71 - 80 yrs
> 80 yrs
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The side of the hernia among cases were as follows  
Side Right Left Bilateral 
Number of 
Subjects 
60 57 33 
 
 
 
There were 7 cases of recurrent hernias among the cases. Out of which 2 
were bilateral, 4 left sided and 1 was right sided hernia. The remaining 143 hernias 
were new onset hernias. 
  
Right
Left
Bilateral
 54 
 
Type of hernia – Direct or Indirect 
 
Type of Hernia Direct Indirect 
Number of Subjects 102 48 
 
 
 
All recurrent hernias were of direct variety only. All the subjects were 
having reducible hernia only. 
  
Direct
Indirect
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The control subjects were also selected from the ward from those patients 
admitted for diseases other than Hernia. The control subjects were having different 
illness such as Diabetic Foot, Haemorrhoids, Hydrocele, APD, Acute Gastritis, Ca. 
Rectum, Chronic Pancreatitis, Fissure in ano, Ileocaecal TB, Gastric Outlet 
Obstruction, Cellulites, Varicose Veins, Liver Abscess, Ca. Stomach, POVD, 
Fournier’s Gangrene, Lipoma, Malignant Melanoma, Basal Cell Carcinoma, 
Ca.Colon, Fistula in Ano, Obstructive Jaundice and Ca.Penis. 
Diagnoses among controls 
 
None of the control subjects had inguinal hernia or have had any kind of 
surgery for inguinal hernia in the past. 
0
5
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INTERNATIONAL PROSTATE SYMPTOM SCORE: 
Among the cases 47 subjects were not symptomatic, 54 were mildly 
symptomatic, 46 were moderately symptomatic and 3 were severely symptomatic 
at the time of admission. Among controls, 115 were mildly symptomatic or having 
no symptoms, 29 were moderately symptomatic and 6 were severely symptomatic.  
 
International Prostate Symptom Score of Cases: 
 
 
 
Not Symptomatic
mildly symptomatic
moderately symptomatic
severely symptomatic
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International Prostate Symptom Score of controls 
 
 
 
All subjects who were moderately or severely symptomatic were considered 
as having significant BPH. Hence there were 49 subjects among cases and 35 
subjects among controls were having significant BPH.  
  
Not Symptomatic
mildly symptomatic
moderately symptomatic
severely  symptomatic
 58 
 
Crosstab 
 
   
VAR00001 
Total cases controls 
IPSS ≥8 Count 49 35 84 
% within 
IPSS 
58.3% 41.7% 100.0% 
<8 Count 101 115 216 
% within 
IPSS 
46.8% 53.2% 100.0% 
Total Count 150 150 300 
% within 
IPSS 
50.0% 50.0% 100.0% 
 
Chi square value= 3.24; P value 0.072 
 
Among those scored ≥ 8 in IPSS scores 58.3% were cases and 41.75% were 
controls. However the difference was not found to be statistically significant. 
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PROSTATE VOLUME: 
Among cases, 57 subjects were having prostate volume >20cc and 93 were 
having prostate volume ≤ 20cc. Therefore 57 of 150 cases were taken as having 
significant Benign Prostatic Enlargement. 
Among controls, 48 subjects were having prostate volume > 20cc and 102 
were having prostate volume ≤ 20cc. Therefore 48 of 150 controls were taken as 
having Benign Prostatic Enlargement. 
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Crosstab 
   
VAR00001 
Total cases controls 
Prostate 
volume 
>20cc Count 57 48 105 
% within 
volume 
54.3% 45.7% 100.0% 
≤20cc Count 93 102 195 
% within 
volume 
47.7% 52.3% 100.0% 
Total Count 150 150 300 
% within 
volume 
50.0% 50.0% 100.0% 
 
Chi square= 1.18; P value 0.276 
Among those who had a prostate vol >20 ng/ml, 54.3% were cases and 
45.7% were controls. However the difference is not statistically significant. 
  
 61 
 
Post - Void Residual Urine Volume 
The measurement of Post – void residual urine volume is done by Ultra 
sonogram of abdomen. A volume of > 50ml is taken as significant. But there was 
no significant difference in the distribution of the number of patients with Post – 
void residual urine volume >50ml between cases and controls (19 and 16 
respectively). 
Distribution of Post - Void Residual Urine Volume among Cases and 
Controls: 
 
  
PRV>50ml
Cases
Controls
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PROSTATE SPECIFIC ANTIGEN: 
Among the cases 29 subjects were having PSA > 4ng/ml and 121 were having PSA 
≤ 4ng/ml. Therefore 29 out of 150 cases were taken as having significant Benign 
Prostatic Enlargement. 
Among the controls 32 subjects were having PSA > 4ng/ml and 118 were having 
PSA ≤ 4ng/ml. Therefore 32 out of 150 controls were taken as having significant 
Benign Prostatic Enlargement. 
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Crosstab 
   
VAR00001 Total 
    
cases controls 
  
PSA >  4 
ng/ml 
Count 
29 32 61 
    % within PSA 47.5% 52.5% 100.0% 
  ≤4 
ng/ml 
Count 
121 118 239 
    % within PSA 50.6% 49.4% 100.0% 
Total Count 150 150 300 
  % within PSA 50.0% 50.0% 100.0% 
 
Chi square= 0.185; P value 0.665 
Among those who had PSA value > 4ng/ml, 47.5% were cases and 52.5% 
were controls. However the difference is not statistically significant. 
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CONCLUSION 
 
 Among the cases 117 were having unilateral hernia and 33 were having 
bilateral hernias. 
 Right sided hernia was slightly more common than the left sided hernias (60 
vs 57). 
 Univariate analysis of association between Inguinal Hernia and Benign 
Prostatic Hyperplasia using International Prostate Symptom Score showed 
no statistically significant association between the two. 
 Univariate analysis of association between Inguinal Hernia and Benign 
Prostatic Hyperplasia using Serum Prostatic Specific Antigen also showed 
no statistically significant association between the two. 
 Prostatic size also did not show any statistically significant association 
between Inguinal Hernia and Benign Prostatic Hyperplasia. 
 There was no significant difference in the distribution of the number of 
patients with Post – void residual urine volume >50ml between cases and 
controls. 
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 Although both Inguinal Hernia and Benign Prostatic Hyperplasia are seen 
with increased frequency in the aged male population, this study showed no 
statistically significant association between the two. Their occurrence 
together is considered a chance co-existence rather than cause and effect. 
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LIMITATIONS OF THE STUDY 
 
 As the Uroflowmetric studies are not available in our hospital, it could 
not be used in this study. Univariate analysis using uroflowmetric 
analysis may better reflect the cause – effect association between 
Inguinal Hernia and Benign Prostatic Hyperplasia as it will better 
assess the obstructive nature of BPH. 
 Age standardization could not be done in this study because of the 
method of selection of cases and controls. 
 Trans Rectal Ultrasonographic assessment of prostatic size could not 
be done in this study as it was not available in our hospital. 
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PROFORMA – CASES 
Basic Details 
Name:      Age/Sex 
IP NO:      DOA: 
Hernia 
Right  ⃝ Left  ⃝  Bilateral  ⃝  Recurrent  ⃝ 
Direct  ⃝ Indirect  ⃝ 
IPSS: 
In the past 
month: 
Not 
at 
All 
Less 
than 
1 in 5 
Times 
Less 
than 
Half 
the 
Time 
Abou
t 
Half 
the 
Time 
More 
than 
Half 
the 
Time 
Alm
ost 
Alwa
ys 
Yo
ur 
sco
re 
Incomplete Emptying: 
How often have you 
had the sensation of not 
emptying your bladder? 
0 1 2 3 4 5  
Frequency: How often 
have you had to urinate 
less than every two 
hours? 
0 1 2 3 4 5  
Intermittency: How 
often have you found 
you stopped and started 
again several times 
when you urinated? 
0 1 2 3 4 5  
Urgency: How often 
have you found it 
difficult to postpone 
urination? 
0 1 2 3 4 5  
Weak Stream: How 
often have you had a 
weak rinary stream? 
0 1 2 3 4 5  
Straining: How often 
have you had to strain 
to start urination? 
0 1 2 3 4 5  
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Nil 
    1 
Time 
    2 
Time 
   3 
Time 
   4 
Time 
   5 
Time 
 
 Nocturia: How many 
times did you typically 
get up at night to 
urinate? 
0 1 2 3 4 5  
Total IPSS 
Score 
       
 
Prostate Volume    : 
Post - void Residual Urine Volume : 
PSA      : 
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PROFORMA CONTROLS 
Basic Details 
Name:      Age/Sex 
IP NO:      DOA: 
Diagnosis: 
IPSS: 
In the past 
month: 
Not 
at 
All 
Less 
than 
1 in 5 
Times 
Less 
than 
Half 
the 
Time 
Abou
t 
Half 
the 
Time 
More 
than 
Half 
the 
Time 
Alm
ost 
Alwa
ys 
Yo
ur 
sco
re 
Incomplete Emptying: 
How often have you 
had the sensation of not 
emptying your bladder? 
0 1 2 3 4 5  
Frequency: How often 
have you had to urinate 
less than every two 
hours? 
0 1 2 3 4 5  
Intermittency: How 
often have you found 
you stopped and started 
again several times 
when you urinated? 
0 1 2 3 4 5  
Urgency: How often 
have you found it 
difficult to postpone 
urination? 
0 1 2 3 4 5  
Weak Stream: How 
often have you had a 
weak rinary stream? 
0 1 2 3 4 5  
Straining: How often 
have you had to strain 
to start urination? 
0 1 2 3 4 5  
  
Nil 
    1 
Time 
    2 
Time 
   3 
Time 
   4 
Time 
   5 
Time 
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 Nocturia: How many 
times did you typically 
get up at night to 
urinate? 
0 1 2 3 4 5  
Total IPSS 
Score 
       
 
Prostate Volume    : 
Post - void Residual Urine Volume : 
PSA      : 
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KEY TO THE MASTER CHART 
 
A  : Age 
IP No  : Inpatient number 
Rt  : Right sided 
Lt  : Left sided 
B/L  : Bilateral 
Rc.  : Recurrent Hernia 
D  : Direct Hernia 
ID  : Indirect Hernia 
Ic.Em  : Incomplete Emptying 
Fr.  : Frequency of Urination 
In.Em  : Intermittent Emptying 
Urg.  : Urgency 
Wk.St.  : Weak Stream 
Str.  : Straining 
Noct.  : Nocturia 
IPSS  : International Prostate Symptom Total Score 
Pr.V  : Prostate volume in cc 
PVR  : Post – void residual urine volume  >50ml 
PSA  : Prostate Specific Antigen 
n/ml  : nanograms/litre 
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MASTER 
CHART 
CASES 
          S.No. Name A IP NO Hernia International Prostate Symptom Score Pr.V PVR PSA 
        Rt
 
Lt
 
B/
L 
Rc
. 
D ID
 
Ic
.E
m
 
Fr
. 
In
.E
m
 
U
rg
. 
W
k.
St
. 
St
r. 
N
oc
t. 
IP
SS
 
      
1 Chinnan 65 77278   *       * 0 1 0 1 1 1 0 4 18   0.3 
2 Murugan 63 77268   *     *   0 0 0 0 1 1 1 3 22   1.6 
3 Veeranan 70 79526  *         * 1 3 1 4 2 3 1 15 28   6.1 
4 Gurusamy 57 79616 *         * 0 1 0 0 1 0 0 2 17   0.6 
5 Andimuthu 64 79586 *       *   1 2 0 2 2 2 1 10 32 * 5.2 
6 Baluchamy 65 79180 *         * 0 0 0 1 1 0 0 2 16   1.2 
7 Shanmugam 75 79432 *       *   3 4 2 4 5 4 3 25 33 * 3.6 
8 Jafer Khan 56 83816   *     *   0 0 0 0 0 0 0 0 17   1.1 
9 Athigavalli 57 84803   *       * 1 1 1 2 2 3 1 11 24   3.9 
10 Saravanamuthu 60 86809 *       *   0 1 0 1 0 0 0 2 17   4.2 
11 Subburam 60 88444 *         * 0 1 0 0 1 0 0 2 22   0.6 
12 Murugan 55 90736     *     * 0 0 0 0 0 0 0 0 24 * 0.9 
13 Palanisamy 73 91005   *     *   1 1 0 2 1 1 1 7 17   0.2 
14 Vetrivel 52 91086 *       *   0 0 0 0 0 1 0 1 18   0.8 
15 Karuppan 69 91038   *     *   1 2 1 3 2 5 2 16 33 * 4.3 
16 Seetapathi 54 92446 *         * 0 0 0 1 0 0 0 1 17   2.1 
17 Kannan 60 92466   *     *   1 2 1 3 4 4 2 17 33   6.2 
18 Manikkam 74 92478   *     *   1 1 1 1 2 1 0 7 28   1.9 
19 Amsadoss 58 92486     *   *   0 0 0 1 1 1 0 3 18   0.1 
20 Alaguraman 61 92512   *     *   0 1 1 3 3 2 1 11 28   2.6 
21 Thangapandi 63 92522 *       *   0 0 0 1 1 2 0 4 17   0.5 
22 Devadoss 70 93033     *     * 1 2 1 4 2 4 3 17 36 * 6 
23 Chinnakalai 78 93101   *     *   1 1 1 1 1 1 0 6 18   2.1 
24 Arunachalam 63 94108   *     *   0 1 0 3 3 3 2 12 28 * 1.3 
25 Palani 55 95814 *         * 0 0 0 1 0 0 0 1 22   3.2 
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26 Kuppusamy 78 95916   *       * 1 3 1 2 4 5 2 18 29   4.7 
27 Selvam 57 99703     *   *   0 2 0 3 3 3 1 12 24   0.3 
28 Thangaraj 55 99884     *   *   0 0 0 0 0 0 0 0 16   0.9 
29 Durai 60 99800 *       *   0 0 1 0 1 0 0 2 15   3 
30 Krishnan 62 99916   *       * 2 2 1 4 3 4 3 19 26   2 
31 Jesuraja 59 10222     *   *   0 1 0 1 1 1 0 4 16   2.2 
32 Raju 60 10216 *       *   0 0 0 0 0 1 1 2 17   3.1 
33 Seetaraman 51 10701 *       *   0 0 0 0 0 0 0 0 16   0.3 
34 Kannan 58 1113 *       *   1 1 0 3 3 3 1 12 36 * 4.3 
35 Krishnamoorthi 68 1120   *       * 1 2 0 2 2 3 1 11 32   4.4 
36 Shanmugam 61 1189   *       * 0 0 0 1 1 0 0 2 17   0.6 
37 Sankar 63 4462 *       *   2 3 1 3 3 3 2 17 28   0.6 
38 Velusamy 60 4883     *   *   0 0 0 0 0 1 0 1 22   0.5 
39 Arumugam 63 4832 *       *   1 2 1 3 2 4 2 15 36 * 3.9 
40 Palanisamy 62 5545 *       *   0 0 0 0 1 1 1 3 19   1 
41 Palsamy 70 5568   *       * 1 1 0 2 2 2 2 10 33 * 4.2 
42 Balamurugan 72 8268   *       * 0 1 0 1 1 1 1 5 18   0.3 
43 Ayyadurai 69 8298 *       *   0 0 0 0 0 0 1 1 17   0.6 
44 Manikkam 57 9959 *       *   0 1 0 0 1 1 1 4 16   0.8 
45 Madasamy 60 9889   *     *   0 0 0 0 0 0 0 0 16   1.1 
46 Palanivel 63 9918   *       * 0 0 0 1 1 2 0 4 18   2.4 
47 Ramu 60 9938 *         * 0 0 0 0 0 0 0 0 18   0.3 
48 Chellaya 66 9899     *   *   0 1 0 3 3 3 2 12 28   0.6 
49 Raju 62 10008     *   *   1 1 1 1 1 1 0 6 17   1.7 
50 Karuppaiya 69 10014   *     *   0 0 0 1 0 0 0 1 17   1.1 
51 Arunachalam 54 10049     *   *   0 0 0 0 0 0 0 0 15   0.1 
52 Muthusamy 70 11563 *         * 0 2 0 3 3 3 1 12 26 * 4.2 
53 Madasamy 62 11711 *       *   0 0 0 2 3 3 3 11 29   4.3 
54 Ambalam 69 11683   *     *   0 1 0 0 0 0 0 1 17   3.1 
55 Selvam 51 11881 *         * 0 0 0 0 0 0 0 0 17   0.1 
56 Rajamani 53 12001   *     *   0 0 0 0 0 0 0 0 16   3.2 
57 Karuppusamy 62 15101 *         * 3 3 3 3 2 4 4 22 36 * 3.9 
58 Durai 77 15188 *       *   3 4 4 4 5 4 4 28 28   5.1 
 76 
 
59 Muniyandi 60 15133     *   *   0 2 2 2 2 5 3 16 16   0.3 
60 Samy 61 15201     *   *   0 0 0 0 0 0 0 0 16   0.2 
61 Jafer Ali 58 18921     * * *   0 0 0 0 0 0 0 0 22   4.1 
62 Natchiyambalam 69 18998   *   * *   1 2 0 0 3 3 4 13 28   3.6 
63 Muthu  72 18455     *     * 0 1 0 0 0 1 0 2 21   3.1 
64 Sivaramakrishnan 54 20492 *       *   0 0 0 0 0 0 0 0 18   0.6 
65 Mookan 78 20522 *         * 1 1 0 1 2 3 2 10 24   0.9 
66 Rajendran 64 54470   *     *   0 0 0 0 1 1 0 2 16   0.5 
67 Samayadurai 65 58510 *       *   0 0 0 0 0 0 0 0 16   0.3 
68 Mayandi 72 55281 *       *   0 1 0 1 1 1 1 5 17   0.1 
69 Maruthu 76 57321   *     *   1 2 1 1 3 3 2 13 32   1.2 
70 Raman 55 57330 *         * 0 0 0 0 0 0 0 0 16   3.3 
71 Kannan 51 57418   *     *   0 0 0 0 0 0 0 0 14   2.1 
72 Aandi 58 58383   *       * 0 1 0 1 0 1 0 3 17   0.9 
73 Jesuraja 63 58630   *     *   1 2 1 1 2 2 1 10 25 * 4.9 
74 Anwar Pasha 60 58644   *       * 0 0 0 0 1 1 0 2 24   0.6 
75 Velu  66 58659 *         * 0 0 0 0 0 0 0 0 17   0.9 
76 Pandi 68 58708 *       *   0 0 0 0 0 0 0 0 18   1.9 
77 Ponnuchami 69 60019     *   *   0 1 1 2 2 2 2 10 28   3.2 
78 Arumugam 71 60083   *   * *   1 1 1 1 1 1 1 7 16   3 
79 Palani 66 61191 *         * 0 0 0 0 0 0 0 0 16   0.8 
80 Karuppan 52 61837 *         * 0 0 0 0 0 0 0 0 16   0.1 
81 Karthikeyan 57 61438     *   *   0 0 0 0 0 0 1 1 17   0.2 
82 Sami 59 62921   *     *   0 0 0 0 0 1 1 2 18   0.1 
83 Kizhavan 71 62983   *       * 1 2 1 3 3 3 4 17 32 * 5.6 
84 Chinnakalai 65 62953   *     *   0 0 0 0 1 3 3 7 16   0.5 
85 Karuppaiah 74 64963   *   * *   1 2 1 2 2 2 2 12 28   3.1 
86 Palani  78 65533 *       *   0 0 1 3 3 3 3 13 28   3.9 
87 Murugan 58 65601   *     *   0 0 0 0 0 0 0 0 17   0.3 
88 Raja  62 65608 *       *   0 0 0 0 1 0 1 2 16   1.3 
89 Appu 64 66633   *       * 1 1 0 1 2 2 2 9 30   5.1 
90 Karuppan 66 66711 *       *   0 1 0 0 0 0 0 1 16   4.3 
91 Karmegam 55 67001 *     * *   0 0 0 0 0 0 0 0 18   0.2 
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92 Pandi 65 67013     *   *   0 2 0 2 4 3 3 14 35 * 3.3 
93 Vadivel 67 67038   *     *   1 1 1 1 1 1 1 7 15   3.6 
94 Rajendran 68 67059   *       * 0 0 0 0 0 0 0 0 16   2.6 
95 Andisamy 60 67383 *         * 0 0 0 0 0 0 1 1 15   2.4 
96 Murugan 55 70081   *     *   0 0 0 1 0 1 0 2 15   0.3 
97 Rajan 53 73183 *       *   0 0 0 0 0 0 0 0 16   0.9 
98 Thirumalai 56 74101     *   *   0 1 0 0 0 0 0 1 18   1.9 
99 Arumugam 58 76280     *   *   0 0 0 0 0 0 1 1 17   0.2 
100 Duraipandi 65 76306   *       * 1 2 1 2 4 4 1 15 27   4.1 
101 Pandi 59 78801 *       *   0 0 0 0 0 0 0 0 24   3.9 
102 Sundararajan 53 79113   *     *   0 0 0 0 0 0 0 0 19   0.3 
103 Gurusamy 52 79233     *   *   0 0 0 0 0 0 0 0 18   0.6 
104 Chinnan 71 80413 *         * 2 2 1 2 3 3 4 17 38 * 6.1 
105 Nallendrababu 60 80451     *   *   1 2 1 2 2 2 3 13 28   1.6 
106 Kalailingam 78 80501     *   *   1 2 2 2 3 3 1 14 28   1.2 
107 Alagesan 65 80523 *       *   0 0 0 0 0 0 0 0 17   3 
108 Ramuthevar 51 80557   *       * 0 0 0 0 0 0 0 0 17   0.3 
109 Ayyavu 67 83588 *         * 0 1 1 2 2 3 0 9 18   0.6 
110 Muthu 60 83838     *   *   0 0 0 0 0 0 0 0 18   4.1 
111 Selvam 63 91300   *       * 1 0 0 0 0 1 1 3 32   3.4 
112 Lakshmanan 70 91510 *         * 1 2 1 0 4 3 2 13 28   4.6 
113 Seethapathi 56 91683 *       *   0 0 0 0 0 0 0 0 18   0.9 
114 Devadoss 62 92004   *     *   0 1 0 0 0 0 1 2 17   0.6 
115 Krishnan 51 94183     *     * 0 0 0 0 0 0 0 0 16   0.4 
116 Velusamy 75 94204 *       *   1 1 0 0 0 2 1 5 22 * 0.4 
117 Sakthivel 56 94381   *       * 0 0 0 0 0 0 0 0 16   3.9 
118 Sakkaraithevar 85 94386 *       *   1 2 2 3 3 3 3 17 29 * 2.1 
119 Ramar 62 97101   *     *   0 0 0 0 0 0 0 0 18   1 
120 Dhanabalasingam 75 97286   *     *   0 2 1 3 2 3 1 12 26   4.1 
121 Murugan 62 97212 *       *   0 0 0 0 0 1 0 1 17   3.2 
122 Aandi 60 381 *       *   0 0 0 0 0 0 0 0 16   3 
123 Gurusamy 59 508     *   *   0 0 0 0 0 0 1 1 16   1 
124 Sikkender 52 1825 *       *   0 0 0 0 0 0 0 0 15   1 
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125 Pandi 60 5039 *       *   0 1 1 2 2 2 1 9 24   0.9 
126 Mani 56 7929 *         * 0 0 0 0 0 0 0 0 16   0.6 
127 Subbu 52 8061 * *       * 0 0 0 0 0 0 0 0 16   0.5 
128 Ammasi 60 9781     *     * 0 0 0 0 0 1 1 2 17   1.2 
129 Ramu 68 9798   *     *   1 1 0 1 2 2 1 8 32   4.3 
130 Vanniyaperumal 51 20101   *     *   0 0 0 0 0 0 0 0 15   3.3 
131 Thangapandi 58 20118   *     *   0 0 0 0 0 0 0 0 16   0.2 
132 Rasu 65 20645     *     * 0 0 0 0 0 1 1 2 16   0.3 
133 Chinnappan 70 22328     * * *   1 2 1 1 2 2 1 10 15   0.3 
134 Aandi 74 22338   *     *   2 2 1 2 3 4 3 17 36 * 5.1 
135 Kannan 60 26890 *       *   1 1 0 0 0 1 0 3 17   0.9 
136 Raja 52 30340 *       *   0 0 0 0 0 0 0 0 18   0.6 
137 Adaikan 65 35203     *   *   0 1 0 0 0 1 0 2 17   0.6 
138 Subramaniyan 55 36882     *   *   0 0 0 0 0 0 0 0 17   0.3 
139 Muthukalai 65 38511   *     *   0 2 0 0 3 3 3 11 26   1.6 
140 Velusamy 67 40101     *   *   0 1 0 0 0 0 0 1 17   1.9 
141 Manimaran 55 40118 *       *   0 0 0 0 0 0 0 0 19   0.9 
142 Hariram 54 57883   *       * 0 1 0 0 0 0 0 1 19   0.3 
143 Adaikan 68 62182   *     *   1 2 2 1 1 1 1 9 24   4.3 
144 Sundararajan 52 62291 * *       * 0 0 0 0 0 0 0 0 16   3.2 
145 Arumugam 51 92913 *         * 0 0 0 0 0 0 0 0 15   3.3 
146 Palanisamy 64 63011     *   *   1 1 0 1 2 2 1 8 26   3.9 
147 Gurusamy 55 64745     *   *   0 0 0 0 0 0 0 0 19   0.6 
148 Pandi 56 65639 *       *   0 0 0 0 0 0 0 0 21   3.2 
149 Raja 53 65990 *       *   0 0 0 0 0 0 0 0 16   0.3 
150 Amavasi 69 69512   *   * *   1 2 2 1 1 2 2 11 33 * 4.2 
 
  
MASTER CHART  -  CONTROLS 
 S.No. Name A IP NO Diagnosis International Prostate Symptom Score Pr.V PRV PSA 
 79 
 
          
Ic
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. 
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N
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n/
m
l 
1 Pitchai 70 77286 Diabetic Foot 2 2 1 2 3 3 1 14 33   4.2 
2 Ponnusamy 64 77292 Hemorrhoids 0 0 0 0 0 0 1 1 17   2.3 
3 Mariappan 56 78112 Hydrocele 0 0 0 0 0 0 0 0 18   2.8 
4 Manikkam 72 79510 Ca.Rectum 1 0 0 2 0 0 0 3 17   2.9 
5 Ayyavu 81 79624 Chronic Pancreatitis 1 3 1 3 4 4 2 18 36 * 3.1 
6 Sakthivel 53 82195 Acute Gastritis 0 0 0 0 0 0 0 0 16   1.8 
7 Selvam 61 82973 Gastric Outlet Obstruction 0 0 0 1 0 0 0 1 17   3 
8 Kathiresan 60 83402 Diabetic Foot 0 0 0 0 0 1 0 1 18   3.6 
9 Velmurugan 56 84110 Varicose veins 0 1 0 1 0 1 0 3 15   2.8 
10 Baskaran 61 87197 Liver abscess 0 0 0 0 0 0 0 0 17   3.1 
11 Prabakaran 71 88003 Fournier's Gangrene 0 1 1 0 1 0 0 3 18   1.9 
12 Palani 82 90219 Acid Peptic Disease 1 0 0 0 2 2 0 5 16   1.8 
13 Syed Mohammed 53 90993 Hemorrhoids 2 2 2 3 3 3 4 19 37 * 5.1 
14 Balanayagam 61 91218 Ca.Stomach 0 0 0 0 0 0 0 0 16   2.3 
15 Natchimuthu 69 91784 Malignant melanoma 0 1 0 0 0 1 0 2 21   4.2 
16 Periyakaruppan 71 92763 Fissure in ano 1 2 1 3 3 3 2 15 28   4.5 
17 Ayyappan 83 92901 Ca.colon 1 1 1 1 1 1 0 6 26   3.6 
18 Muniyandi 62 92987 Hemorrhoids 0 0 0 0 0 0 0 0 18   3.2 
19 Palpandi 65 93107 POVD 0 1 0 0 0 0 0 1 17   2.8 
20 Kannan 56 93525 Cellulitis 0 0 0 0 0 0 0 0 17   1.9 
21 Sudalaimuthu 59 93746 Diabetic Foot 0 0 0 0 0 0 1 1 18   1.2 
22 Ammavasi 78 94399 Lipoma back 1 1 2 1 3 3 4 15 22   4.9 
23 Chinnakaruppan 61 94865 Fissure in ano 0 0 0 0 0 0 0 0 22   3.7 
24 Natchiyappan 63 95717 Hemorrhoids 0 2 1 2 2 2 1 10 24   6.1 
25 Baskaran 65 95886 Ileocaecal TB 0 0 0 0 0 0 0 0 17   1.9 
26 Namasivayam 68 96392 Diabetic Foot 0 1 0 0 0 1 0 2 18   3.7 
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27 Sundareshwaran 71 96801 Hemorrhoids 0 0 0 0 0 0 0 0 17   2 
28 Rathinam 58 97889 Cellulitis 0 0 0 0 0 0 1 1 18   4.3 
29 Alagappan 64 98241 Obstructive Jaundice 0 0 0 0 0 1 0 1 19   5.2 
30 Kulandaivel 62 98369 Ca.Penis 1 2 1 3 3 3 4 17 36 * 6.1 
31 Saravanamuthu 63 106231 Hemorrhoids 0 0 0 0 1 1 0 2 18   2.5 
32 Arivuselvam 58 102182 Diabetic Foot 0 0 0 0 0 0 0 0 19   1.6 
33 Manickam 71 102014 Varicose veins 0 0 0 0 0 0 0 0 23   4.1 
34 Sudalaimuthu 78 1217 Fissure in ano 1 0 0 0 0 0 1 2 19   0.9 
35 Sivankalai 64 1281 Gastric Outlet Obstruction 0 0 0 0 0 0 0 0 19   3.3 
36 Karuppaih 59 1385 Cellulitis 0 0 0 2 0 0 1 3 23   2.2 
37 Hassen khan 62 4432 Hemorrhoids 2 2 1 3 3 4 2 17 32 * 7.3 
38 Nagan 58 4483 POVD 0 0 0 0 1 1 0 2 18   2.2 
39 Krishnamoorthy 64 4842 Cellulitis 0 1 0 2 0 0 0 3 16   2.3 
40 Karuppaih 73 5551 Diabetic Foot 1 3 3 3 3 4 3 20 38 * 5.3 
41 Sudalaimuthu 63 5597 Diabetic Foot 0 0 0 0 1 1 0 2 22   4.6 
42 Ramar 67 8061 Ca.Penis 0 1 0 0 0 1 1 3 18   0.8 
43 Ramaiah 59 8088 Acid Peptic Disease 0 0 0 0 0 0 0 0 16   1.4 
44 Ramu 73 9781 Cellulitis 2 2 1 2 3 3 1 14 27   5.5 
45 chellaiah 77 9704 Hemorrhoids 1 1 1 2 2 2 1 10 28   6.1 
46 Anbazhagan 68 9981 Liver abscess 0 0 0 0 0 0 0 0 17   0.9 
47 Aruljesudason 61 9920 Hemorrhoids 1 2 1 3 4 3 2 16 32 * 3.2 
48 Kannabiran 59 9916 Fournier's Gangrene 0 0 0 0 1 1 1 3 18   3.6 
49 Muthusamy 72 10112 Fistula in ano 1 3 0 0 0 2 3 9 33   4.7 
50 Thangarsu 60 10203 Cellulitis 0 1 0 0 1 1 0 3 17   0.6 
51 Arasan 59 11638 Diabetic Foot 0 0 0 0 0 0 0 0 22   4.9 
52 Pandidurai 58 12429 Ca.Stomach 0 0 1 0 1 1 1 0 16   9 
53 Surendran 63 12873 Hemorrhoids 1 1 1 1 0 1 0 5 18   1.2 
54 Joseph 67 13108 Cellulitis 0 0 0 0 0 1 1 2 18   1.3 
55 Balamurugan 71 13910 Varicose veins 0 1 1 1 1 0 0 4 32   1.7 
56 Aandiyappan 72 14539 Diabetic Foot 1 3 1 4 4 4 3 20 36 * 5.2 
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57 Nagendran 59 14800 Lipoma back 0 0 0 0 0 0 0 0 18   1.3 
58 Thirumalai 60 15006 Obstructive Jaundice 0 1 0 0 0 1 0 2 17   1.5 
59 Anwar shahid 61 15123 Acid Peptic Disease 0 0 0 0 0 1 1 2 18   1.9 
60 Chellapandi 68 15293 Hydrocele 1 1 0 0 0 1 0 3 16   0.5 
61 Baranitharan 60 16819 Hemorrhoids 0 0 0 0 0 0 1 1 18   0.6 
62 Basha ali 75 17801 Diabetic Foot 0 0 0 2 3 3 0 8 32   4.1 
63 Mayandi 59 17912 Ca.Rectum 0 0 0 1 0 0 1 2 17   0.1 
64 Pandidurai 61 18536 Cellulitis 1 0 0 0 0 0 0 1 18   0.8 
65 Ariularasan 80 18773 Diabetic Foot 0 0 0 0 0 0 3 3 28 * 4.1 
66 Boominathan 61 19214 Acid Peptic Disease 0 0 0 0 0 1 1 2 18   0.6 
67 Raja 54 19348 Cellulitis 1 2 1 2 3 3 3 15 24   4.2 
68 Madasamy 62 19876 Cellulitis 0 0 0 0 1 0 1 2 18   0.9 
69 Velmurugan 71 20312 Varicose veins 0 1 0 0 1 1 0 3 19   0.8 
70 Annamalai 69 20610 Hemorrhoids 0 1 0 0 1 1 1 4 28   1.5 
71 Chandrasekaran 62 28312 Acid Peptic Disease 0 1 0 1 1 0 0 3 19   3.9 
72 Jesuraja 73 29103 Acid Peptic Disease 0 0 0 1 1 1 1 4 18   2.1 
73 Baskaran 60 30943 Hemorrhoids 1 2 0 1 2 3 4 13 36 * 5.5 
74 Syed Ibrahim 81 38412 Cellulitis 0 1 0 1 1 1 2 6 32   0.6 
75 Sivaraman 71 40198 Diabetic Foot 0 1 0 0 0 0 0 1 18   2.2 
76 Kannan 63 43619 Hemorrhoids 0 0 0 0 0 3 2 5 22   3 
77 Palani 72 45900 Ca.Penis 0 0 0 0 0 0 0 0 18   0.6 
78 Ramakrishnan 61 48665 Diabetic Foot 0 0 0 0 1 1 0 2 17   0.7 
79 Chandran 60 50012 Diabetic Foot 0 1 0 0 1 1 1 4 18   1.1 
80 Palpandi 59 53118 Cellulitis 0 0 0 0 0 0 1 1 17   2.5 
81 Ammavasi 64 55809 Acid Peptic Disease 0 1 0 1 1 1 1 5 24   3.6 
82 Ulaganathan 71 56962 Fissure in ano 1 2 1 4 3 3 3 17 18   3.4 
83 Senthilvel 62 57361 Liver abscess 0 1 0 0 1 1 0 3 18   0.8 
84 Karuppaih 83 62646 Diabetic Foot 3 3 2 4 5 5 5 27 38   5.1 
85 Selvaraj 58 63129 Cellulitis 1 0 1 1 0 1 1 5 17   0.9 
86 Anbazhagan 65 64080 Lipoma 0 0 0 1 0 1 0 2 16   0.3 
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87 Rajasekaran 54 65274 Ca.Stomach 0 0 0 1 1 1 0 3 17   0.1 
88 Karuppan 56 66918 Hemorrhoids 0 1 1 1 0 0 0 3 18   1 
89 Chinnasamy 68 67205 Hemorrhoids 0 0 0 0 0 0 0 0 18   1.5 
90 Venkateswaran 70 67313 Gastric Outlet Obstruction 0 0 1 0 1 1 1 4 19   1.3 
91 Ambalam 70 68516 Ca.colon 0 1 0 0 0 0 2 3 28   3.9 
92 Pasha 72 68565 Acid Peptic Disease 0 1 0 1 1 1 1 5 19   3.1 
93 Mayilvahanan 61 69129 Cellulitis 0 0 0 0 0 0 0 0 17   0.2 
94 Pitchai 65 71193 Diabetic Foot 1 2 1 3 4 4 5 20 36 * 6.1 
95 Muniyandi 63 72456 Hemorrhoids 0 0 0 0 1 1 0 2 17   0.3 
96 Annadurai 58 72964 Chronic Pancreatitis 0 0 0 1 0 0 0 1 18   0.5 
97 Manickam 53 73291 Basal Cell Carcinoma 2 3 2 0 4 4 4 19 24 * 1.6 
98 Kathiravan 61 74643 Cellulitis 0 0 0 0 1 1 1 3 18   1.1 
99 Ramachandran 65 74998 Hemorrhoids 0 1 0 1 0 1 1 4 17   2 
100 Natarajan 70 75109 Acid Peptic Disease 0 0 0 2 2 1 0 5 32   2.1 
101 Shanmugam 71 75325 Obstructive Jaundice 1 0 0 1 1 0 1 4 24   2.6 
102 Arumugam 60 76543 Hydrocele 1 0 0 1 1 0 0 3 18   2.4 
103 Palanivel 62 79100 Ca.Penis 1 0 1 1 0 1 1 5 18   2.9 
104 Ponnan 68 79856 Hemorrhoids 1 1 1 2 2 4 4 15 32   4.3 
105 Periyakaruppan 72 80214 POVD 2 2 1 3 3 4 1 16 29   4.1 
106 Sundaram 61 82315 Diabetic Foot 1 1 0 1 1 2   6 24   1.1 
107 chellaiah 70 82963 POVD 2 4 4 3 4 5 4 26 38 * 5.1 
108 Raja 51 83516 Acid Peptic Disease 1 0 1 1 1 1 0 5 18   3.1 
109 Kumarvel 63 83600 Fournier's Gangrene 0 0 0 0 0 0 0 0 17   0.6 
110 Sami 55 83622 Fistula in ano 1 1 1 1 1 2 1 8 29   3.5 
111 Sakthivel 61 83642 Varicose veins 0 0 0 0 0 0 0 0 18   0.2 
112 Vadivel 58 84873 Hemorrhoids 0 0 0 0 0 0 0 0 17   0.1 
113 Sundaram 53 84902 Ca.Rectum 0 1 0 0 0 1 1 3 18   0.3 
114 Kannan 68 85762 Gastric Outlet Obstruction 0 0 0 1 1 2 2 6 19   0.4 
115 Kannabiran 71 86594 Diabetic Foot 0 0 0 0 0 0 0 0 36   0.9 
116 Veluchamy 65 87258 Acute Gastritis 0 1 0 1 1 1 1 5 18   0.6 
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117 Paraman 60 89163 Diabetic Foot 0 1 1 0 1 1 1 5 19   0.5 
118 Rathinam 61 90003 Gastric Outlet Obstruction 0 0 0 1 1 2 3 7 18   1.5 
119 Pandidurai 52 92596 Acute Gastritis 0 1 1 1 2 1 2 8 24   1.9 
120 Balamurugan 59 93860 Diabetic Foot 1 2 1 2 2 2 4 14 28 * 5 
121 Kannan 57 94426 Lipoma 0 0 0 0 0 0 0 0 17   0.2 
122 Palpandi 53 95482 Fissure in ano 0 1 0 1 1 0 1 4 15   0.3 
123 Raja 66 96124 Diabetic Foot 1 1 1 1 1 1 1 7 19   0.3 
124 Aasirvatham 57 2134 Cellulitis 0 1 0 0 0 1 3 5 19   3 
125 Parameswaran 71 4947 Diabetic Foot 2 2 1 4 2 4 3 17 16   0.1 
126 Mayandi 69 5124 Hemorrhoids 0 1 0 1 0 0 0 2 18   0.5 
127 Alagusamy 68 5897 Hydrocele 1 1 2 1 1 1 2 9 28   2.1 
128 Murugan 71 6624 Varicose veins 1 2 1 2 3 3 3 15 24 * 3.1 
129 Dharmendran 50 6756 Gastric Outlet Obstruction 0 0 0 0 0 0 0 0 18   0.5 
130 Gnanasundaram 51 7123 Fissure in ano 0 0 0 0 0 1 1 2 15   0.6 
131 Mohanan 64 8164 Hemorrhoids 0 1 1 0 0 1 0 3 18   0.7 
132 Ganesan 59 8349 Acid Peptic Disease 1 0 0 0 1 0 1 3 17   0.5 
133 Subramani 69 8972 Varicose veins 1 0 1 1 0 1 1 5 18   1.6 
134 Govindarajan 72 9964 Diabetic Foot 1 2 1 3 3 5 4 19 34 * 7 
135 Sankar 54 10294 POVD 0 1 0 1 1 0 1 4 16   3 
136 Pandi 63 14296 Fissure in ano 1 1 1 2 2 3 1 11 28   2.3 
137 Aalappan 52 15812 Chronic Pancreatitis 0 0 1 0 1 1 0 3 16   2.6 
138 Ayadurai 51 19115 Ca.Stomach 1 1 0 1 0 1 0 4 18   3.1 
139 Seetharaman 72 22548 Hemorrhoids 2 2 2 4 5 5 5 25 38 * 4.3 
140 Narendaran 58 27519 Cellulitis 0 0 0 0 0 0 0 0 18   0.3 
141 Aandi 56 31329 Cellulitis 0 1 1 0 1 2 0 5 18   0.3 
142 Manoharan 53 37258 Hemorrhoids 1 0 1 1 0 1 0 4 17   0.2 
143 Sundaram 56 38629 Acid Peptic Disease 1 0 0 0 1 1 0 3 17   0.9 
144 Veerapandi 59 44326 Ileocaecal TB 0 0 0 0 0 0 0 0 18   0.4 
145 Jesudason 58 47293 Hemorrhoids 0 1 0 0 0 0 1 2 15   1.1 
146 Samy 60 55921 Ca.Rectum 2 2 2 3 4 3 1 17 27   1.9 
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147 Muthupandi 55 59664 Hemorrhoids 0 1 0 1 0 0 0 2 16   3.9 
148 Sadik pasha 52 60215 Fissure in ano 1 0 1 1 0 1 1 5 19   3.6 
149 Pandi 61 63816 Acid Peptic Disease 1 2 1 4 4 4 1 17 38   6.1 
150 Alagappan 51 63994 Diabetic Foot 0 0 1 1 1 0 1 4 15   3.1 
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